Brian J. Druker - Publications

Affiliations: 
Oregon Health and Science University, Portland, OR 

133 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, ... ... Druker BJ, et al. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900895. PMID 31880950 DOI: 10.1200/JCO.19.00895  0.4
2019 Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, ... ... Druker BJ, et al. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. Nature Communications. 10: 5455. PMID 31784538 DOI: 10.1038/s41467-019-13364-2  0.4
2019 Agarwal A, Bolosky WJ, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ. Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 31754026 DOI: 10.1073/pnas.1904091116  0.4
2019 Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, et al. Replication timing alterations in leukemia affect clinically relevant chromosome domains. Blood Advances. 3: 3201-3213. PMID 31698451 DOI: 10.1182/bloodadvances.2019000641  0.4
2019 Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, ... ... Druker BJ, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. PMID 31543464 DOI: 10.1016/j.ccell.2019.08.004  0.4
2019 Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, ... ... Druker BJ, et al. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. PMID 31366621 DOI: 10.1182/blood.2019000611  0.4
2019 Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, et al. The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells. Cancer Discovery. PMID 31048320 DOI: 10.1158/2159-8290.CD-19-0125  0.4
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30924767 DOI: 10.7554/eLife.47174  0.4
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/eLife.40033  0.4
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/eLife.40033  0.4
2019 Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, ... ... Druker BJ, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications. 10: 244. PMID 30651561 DOI: 10.1038/s41467-018-08263-x  0.4
2019 Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR. Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. Leukemia Research. PMID 30642575 DOI: 10.1016/j.leukres.2018.11.010  0.4
2018 Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, ... ... Druker BJ, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. PMID 30333627 DOI: 10.1038/s41586-018-0623-z  0.4
2018 Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar R, Gilheeney SW, deCarvalho AC, Mikkelsen T, Van Meir EG, Ladanyi M, Druker BJ. Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30171048 DOI: 10.1158/1078-0432.CCR-18-1052  0.4
2018 Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 30082821 DOI: 10.1038/s41375-018-0225-7  0.4
2018 Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 9: 24576-24589. PMID 29872489 DOI: 10.18632/oncotarget.25191  0.4
2018 Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. PMID 29743719 DOI: 10.1038/s41375-018-0112-2  0.4
2018 Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK. Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia. Haematologica. PMID 29567769 DOI: 10.3324/haematol.2018.190926  0.4
2017 Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ, Druker BJ, Tyner JW, Gill PS. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644. PMID 29296810 DOI: 10.1182/bloodadvances.2017005694  0.4
2017 Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, et al. A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. PMID 29284681 DOI: 10.3324/haematol.2017.165282  0.4
2017 Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, et al. CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29078326 DOI: 10.1073/pnas.1708268114  0.4
2017 Degnin M, Agarwal A, Tarlock K, Meshinchi S, Druker BJ, Tognon CE. Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens. Journal of Pediatric Hematology/Oncology. PMID 28906323 DOI: 10.1097/MPH.0000000000000946  0.4
2017 Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, ... ... Druker BJ, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. PMID 28784769 DOI: 10.1073/pnas.1703094114  0.4
2017 Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Reports. 18: 3204-3218. PMID 28355571 DOI: 10.1016/j.celrep.2017.03.018  0.4
2017 Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, et al. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget. PMID 28186983 DOI: 10.18632/oncotarget.15146  0.4
2016 Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Research. PMID 27671675 DOI: 10.1158/0008-5472.CAN-15-3569  0.4
2016 Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Science Translational Medicine. 8: 354ra114. PMID 27582059 DOI: 10.1126/scitranslmed.aaf5309  0.4
2016 Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gönen M, Tyner JW, Druker BJ, Vu TQ. Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Scientific Reports. 6: 28163. PMID 27320899 DOI: 10.1038/srep28163  0.4
2016 de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte AD, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget. PMID 26755644 DOI: 10.18632/oncotarget.6851  0.4
2015 Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, Tyner JW, Druker BJ. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. CurēUs. 7: e414. PMID 26870618 DOI: 10.7759/cureus.414  0.4
2015 Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, ... ... Druker BJ, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. PMID 26677978 DOI: 10.1158/0008-5472.CAN-15-0817  0.4
2015 Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26673800 DOI: 10.1158/1078-0432.CCR-15-2013  0.4
2015 Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, ... Druker BJ, et al. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. American Journal of Hematology. PMID 26573090 DOI: 10.1002/ajh.24245  0.4
2015 Brooks SA, Luty SB, Lai HY, Morse SJ, Nguyen TK, Royer LR, Agarwal A, Druker BJ, Fleischman AG. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model. Experimental Hematology. PMID 26458983 DOI: 10.1016/j.exphem.2015.09.006  0.4
2015 Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. PMID 26372962 DOI: 10.1073/pnas.1515281112  0.4
2015 Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget. PMID 26254279  0.4
2015 Paten B, Diekhans M, Druker BJ, Friend S, Guinney J, Gassner N, Guttman M, James Kent W, Mantey P, Margolin AA, Massie M, Novak AM, Nothaft F, Pachter L, Patterson D, et al. The NIH BD2K center for big data in translational genomics. Journal of the American Medical Informatics Association : Jamia. PMID 26174866 DOI: 10.1093/jamia/ocv047  0.4
2015 Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75: 2146-50. PMID 26032424 DOI: 10.1158/0008-5472.CAN-14-1576  0.4
2015 Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8: 39. PMID 25895498 DOI: 10.1186/s13045-015-0132-6  0.4
2015 Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Druker BJ, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/j.ccell.2015.02.003  0.4
2015 Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, Druker BJ, McCarty OJ. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thrombosis Research. 135: 155-60. PMID 25527332 DOI: 10.1016/j.thromres.2014.11.009  0.4
2015 Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75: 880-91. PMID 25432174 DOI: 10.1158/0008-5472.CAN-14-0573  0.4
2015 Beer PA, Knapp DJ, Miller PH, Kannan N, Sloma I, Heel K, Babovic S, Bulaeva E, Rabu G, Terry J, Druker BJ, Loriaux MM, Loeb KR, Radich JP, Erber WN, et al. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. Blood. 125: 504-15. PMID 25370416 DOI: 10.1182/blood-2014-06-581173  0.4
2014 Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, ... ... Druker BJ, et al. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood. 124: 3260-73. PMID 25293778 DOI: 10.1182/blood-2013-04-497040  0.4
2014 Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Science Translational Medicine. 6: 252ra121. PMID 25186176 DOI: 10.1126/scitranslmed.3009073  0.4
2014 Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 3: 67-9. PMID 25180155 DOI: 10.1016/j.lrr.2014.07.002  0.4
2014 Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, ... ... Druker BJ, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 26: 428-42. PMID 25132497 DOI: 10.1016/j.ccr.2014.07.006  0.4
2014 Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: 6383-8. PMID 24733895 DOI: 10.1073/pnas.1403608111  0.4
2014 Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 5: 908-15. PMID 24659719  0.4
2014 Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology. 99: 616-24. PMID 24658916 DOI: 10.1007/s12185-014-1566-2  0.4
2014 Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2092-103. PMID 24436473 DOI: 10.1158/1078-0432.CCR-13-2575  0.4
2014 Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood. 123: 1516-24. PMID 24408322 DOI: 10.1182/blood-2013-07-518381  0.4
2014 Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. The Journal of Biological Chemistry. 289: 5820-7. PMID 24403076 DOI: 10.1074/jbc.M113.508440  0.4
2014 Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology. 164: 223-32. PMID 24383843 DOI: 10.1111/bjh.12618  0.4
2013 Bottomly D, Ryabinin PA, Tyner JW, Chang BH, Loriaux MM, Druker BJ, McWeeney SK, Wilmot B. Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine. Genome Medicine. 5: 103. PMID 24286512 DOI: 10.1186/gm509  0.4
2013 Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 110: 19519-24. PMID 24218589 DOI: 10.1073/pnas.1319583110  0.4
2013 Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. 110: 19513-8. PMID 24154728 DOI: 10.1073/pnas.1311707110  0.4
2013 Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 122: 3628-31. PMID 24081659 DOI: 10.1182/blood-2013-06-509976  0.4
2013 Vainstein V, Eide CA, O'Hare T, Shukron O, Druker BJ. Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Blood. 122: 3331-4. PMID 24062017 DOI: 10.1182/blood-2012-08-452409  0.4
2013 Eide CA, Druker BJ, O'Hare T. Kinase inhibitor therapy in CML: it's what's inside that counts. Oncotarget. 4: 1332-3. PMID 23934763 DOI: 10.18632/oncotarget.1271  0.4
2013 Aslam MI, Hettmer S, Abraham J, Latocha D, Soundararajan A, Huang ET, Goros MW, Michalek JE, Wang S, Mansoor A, Druker BJ, Wagers AJ, Tyner JW, Keller C. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma. Molecular Cancer Research : McR. 11: 1303-13. PMID 23928059 DOI: 10.1158/1541-7786.MCR-12-0598  0.4
2013 Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Research. 73: 5775-86. PMID 23887971 DOI: 10.1158/0008-5472.CAN-13-1318  0.4
2013 Dao KH, Rotelli MD, Brown BR, Yates JE, Rantala J, Tognon C, Tyner JW, Druker BJ, Bagby GC. The PI3K/Akt1 pathway enhances steady-state levels of FANCL. Molecular Biology of the Cell. 24: 2582-92. PMID 23783032 DOI: 10.1091/mbc.E13-03-0144  0.4
2013 Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, ... ... Druker BJ, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. The New England Journal of Medicine. 368: 1781-90. PMID 23656643 DOI: 10.1056/NEJMoa1214514  0.4
2013 O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, ... ... Druker BJ, et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Research. 73: 3356-70. PMID 23576564 DOI: 10.1158/0008-5472.CAN-12-3904  0.4
2013 Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC. Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Translational Oncology. 6: 158-68. PMID 23544168 DOI: 10.1593/tlo.12307  0.4
2013 Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, ... ... Druker BJ, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discovery. 3: 564-77. PMID 23471820 DOI: 10.1158/2159-8290.CD-12-0504  0.4
2013 Bottomly D, Wilmot B, Tyner JW, Eide CA, Loriaux MM, Druker BJ, McWeeney SK. HitWalker: variant prioritization for personalized functional cancer genomics. Bioinformatics (Oxford, England). 29: 509-10. PMID 23303510 DOI: 10.1093/bioinformatics/btt003  0.4
2013 Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, ... ... Druker BJ, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 121: 489-98. PMID 23223358 DOI: 10.1182/blood-2012-05-431379  0.4
2013 Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. The Journal of Pharmacology and Experimental Therapeutics. 344: 378-87. PMID 23220742 DOI: 10.1124/jpet.112.200832  0.4
2013 Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, ... ... Druker BJ, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Research. 73: 285-96. PMID 23087056 DOI: 10.1158/0008-5472.CAN-12-1906  0.4
2012 Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 367: 2075-88. PMID 23190221 DOI: 10.1056/NEJMoa1205127  0.4
2012 Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 22: 656-67. PMID 23153538 DOI: 10.1016/j.ccr.2012.08.027  0.4
2012 Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 426: 363-8. PMID 22960170 DOI: 10.1016/j.bbrc.2012.08.092  0.4
2012 Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 120: 3898-905. PMID 22915637 DOI: 10.1182/blood-2012-02-410688  0.4
2012 Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood. 120: 2658-68. PMID 22889761 DOI: 10.1182/blood-2011-05-355396  0.4
2012 Qiu X, Guo G, Chen K, Kashiwada M, Druker BJ, Rothman PB, Chen JL. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia (New York, N.Y.). 14: 547-58. PMID 22787435 DOI: 10.1596/neo.12230  0.4
2012 Dao KH, Rotelli MD, Petersen CL, Kaech S, Nelson WD, Yates JE, Hanlon Newell AE, Olson SB, Druker BJ, Bagby GC. FANCL ubiquitinates β-catenin and enhances its nuclear function. Blood. 120: 323-34. PMID 22653977 DOI: 10.1182/blood-2011-11-388355  0.4
2012 Ryba T, Battaglia D, Chang BH, Shirley JW, Buckley Q, Pope BD, Devidas M, Druker BJ, Gilbert DM. Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. Genome Research. 22: 1833-44. PMID 22628462 DOI: 10.1101/gr.138511.112  0.4
2012 Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 97: 731-8. PMID 22315495 DOI: 10.3324/haematol.2011.045666  0.4
2012 Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KR. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. British Journal of Haematology. 157: 507-10. PMID 22299775 DOI: 10.1111/j.1365-2141.2012.09039.x  0.4
2012 Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatric Blood & Cancer. 59: 576-9. PMID 22038978 DOI: 10.1002/pbc.23383  0.4
2011 Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell. 20: 715-27. PMID 22169110 DOI: 10.1016/j.ccr.2011.11.004  0.4
2011 Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of Experimental Medicine. 208: 2163-74. PMID 21911423 DOI: 10.1084/jem.20110304  0.4
2011 O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 118: 5250-4. PMID 21908430 DOI: 10.1182/blood-2011-05-349191  0.4
2011 Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, ... Druker BJ, et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 118: 6392-8. PMID 21860020 DOI: 10.1182/blood-2011-04-348144  0.4
2011 Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, Levine J, Neff TL, Patterson J, Presnell A, McKinley A, Winter LJ, Dewey C, Harlow A, Barney O, ... Druker BJ, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. The Journal of Molecular Diagnostics : Jmd. 13: 504-13. PMID 21726664 DOI: 10.1016/j.jmoldx.2011.04.003  0.4
2011 Gu TL, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi SP, Druker BJ, Heinrich MC, Rush J, Polakiewicz RD. Survey of activated FLT3 signaling in leukemia. Plos One. 6: e19169. PMID 21552520 DOI: 10.1371/journal.pone.0019169  0.4
2011 Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research. 71: 3189-95. PMID 21505103 DOI: 10.1158/0008-5472.CAN-10-3224  0.4
2011 Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Molecular Cancer Therapeutics. 10: 1028-35. PMID 21482694 DOI: 10.1158/1535-7163.MCT-10-1044  0.4
2011 Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. The Journal of Clinical Investigation. 121: 396-409. PMID 21157039 DOI: 10.1172/JCI35721  0.4
2011 O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 212-21. PMID 21098337 DOI: 10.1158/1078-0432.CCR-09-3314  0.4
2011 Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117: 591-4. PMID 20959606 DOI: 10.1182/blood-2010-03-275305  0.4
2010 Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ. A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Research. 70: 7325-35. PMID 20807813 DOI: 10.1158/0008-5472.CAN-10-0607  0.4
2010 Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 116: 3758-65. PMID 20679528 DOI: 10.1182/blood-2010-03-273979  0.4
2010 Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Research. 70: 6233-7. PMID 20670955 DOI: 10.1158/0008-5472.CAN-10-0429  0.4
2010 Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 12469-74. PMID 20616057 DOI: 10.1073/pnas.1005114107  0.4
2010 Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 18: 74-87. PMID 20609354 DOI: 10.1016/j.ccr.2010.04.025  0.4
2010 Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 116: 3278-85. PMID 20519627 DOI: 10.1182/blood-2008-10-183665  0.4
2010 Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115: 5232-40. PMID 20385788 DOI: 10.1182/blood-2009-05-223727  0.4
2010 Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 424-30. PMID 20008622 DOI: 10.1200/JCO.2009.25.3724  0.4
2010 McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 115: 315-25. PMID 19837975 DOI: 10.1182/blood-2009-03-210732  0.4
2009 O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, ... ... Druker BJ, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16: 401-12. PMID 19878872 DOI: 10.1016/j.ccr.2009.09.028  0.4
2009 Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. Plos One. 4: e7439. PMID 19823681 DOI: 10.1371/journal.pone.0007439  0.4
2009 Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 114: 4944-53. PMID 19779040 DOI: 10.1182/blood-2009-04-214221  0.4
2009 Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood. 114: 3459-63. PMID 19706883 DOI: 10.1182/blood-2007-10-113969  0.4
2009 Scholl B, Liu HY, Long BR, McCarty OJ, O'Hare T, Druker BJ, Vu TQ. Single particle quantum dot imaging achieves ultrasensitive detection capabilities for Western immunoblot analysis. Acs Nano. 3: 1318-28. PMID 19453141 DOI: 10.1021/nn9000353  0.4
2009 Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proceedings of the National Academy of Sciences of the United States of America. 106: 8695-700. PMID 19433805 DOI: 10.1073/pnas.0903233106  0.4
2009 Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 115: 551-60. PMID 19117345 DOI: 10.1002/cncr.24066  0.4
2009 Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 113: 1749-55. PMID 19075190 DOI: 10.1182/blood-2008-04-152157  0.4
2008 Chou CJ, O'Hare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM. Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. Plos One. 3: e3593. PMID 18974832 DOI: 10.1371/journal.pone.0003593  0.4
2008 Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Molecular and Cellular Biology. 28: 6496-509. PMID 18694961 DOI: 10.1128/MCB.00477-08  0.4
2008 Agarwal A, Bumm TGP, Corbin AS, O'Hare T, Loriaux M, Van Dyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease Blood. 112: 1960-1970. PMID 18559973 DOI: 10.1182/blood-2007-09-113860  0.4
2008 Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. The Journal of Molecular Diagnostics : Jmd. 10: 177-80. PMID 18276770 DOI: 10.2353/jmoldx.2008.070128  0.4
2008 Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 111: 4022-8. PMID 18256322 DOI: 10.1182/blood-2007-10-116475  0.4
2008 Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, ... ... Druker BJ, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/blood-2007-07-101394  0.4
2008 Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 111: 2238-45. PMID 18025156 DOI: 10.1182/blood-2007-06-097253  0.4
2007 Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, ... ... Druker BJ, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 12: 501-13. PMID 18068628 DOI: 10.1016/j.ccr.2007.11.005  0.4
2007 Thomas EK, Cancelas JA, Chae HD, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Setchell KD, Zheng Y, Harris CE, Williams DA. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 12: 467-78. PMID 17996650 DOI: 10.1016/j.ccr.2007.10.015  0.4
2007 Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6136-43. PMID 17947479 DOI: 10.1158/1078-0432.CCR-07-1112  0.4
2007 Chen Y, Choong LY, Lin Q, Philp R, Wong CH, Ang BK, Tan YL, Loh MC, Hew CL, Shah N, Druker BJ, Chong PK, Lim YP. Differential expression of novel tyrosine kinase substrates during breast cancer development. Molecular & Cellular Proteomics : McP. 6: 2072-87. PMID 17855441 DOI: 10.1074/mcp.M700395-MCP200  0.4
2007 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/JCI31095  0.4
2007 Chen Y, Low TY, Choong LY, Ray RS, Tan YL, Toy W, Lin Q, Ang BK, Wong CH, Lim S, Li B, Hew CL, Sze NS, Druker BJ, Lim YP. Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells. Proteomics. 7: 2384-97. PMID 17570516 DOI: 10.1002/pmic.200600968  0.4
2007 Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, Reeves C, Popova L, Lee K, Heinrich MC, Rush J, Daibata M, Miyoshi I, Gilliland DG, Druker BJ, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 110: 323-33. PMID 17360941 DOI: 10.1182/blood-2006-10-052282  0.4
2007 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109: 2303-9. PMID 17138817 DOI: 10.1182/blood-2006-09-047266  0.4
2006 Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine. 355: 2408-17. PMID 17151364 DOI: 10.1056/NEJMoa062867  0.4
2006 Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Research. 66: 11156-65. PMID 17145859 DOI: 10.1158/0008-5472.CAN-06-2210  0.4
2006 Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biological Research For Nursing. 8: 157-69. PMID 17003255 DOI: 10.1177/1099800406290932  0.4
2006 Gu TL, Goss VL, Reeves C, Popova L, Nardone J, Macneill J, Walters DK, Wang Y, Rush J, Comb MJ, Druker BJ, Polakiewicz RD. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood. 108: 4202-4. PMID 16946300 DOI: 10.1182/blood-2006-06-026666  0.4
2006 DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 108: 3674-81. PMID 16902153 DOI: 10.1182/blood-2006-02-005702  0.4
2006 Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Molecular and Cellular Biology. 26: 6082-6093. PMID 16880519 DOI: 10.1128/MCB.02202-05  0.4
2006 Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, ... ... Druker BJ, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10: 65-75. PMID 16843266 DOI: 10.1016/j.ccr.2006.06.002  0.4
2006 Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 108: 2332-8. PMID 16772610 DOI: 10.1182/blood-2006-02-004580  0.4
Show low-probability matches.